Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: BiCNU Clear all
Completed Phase 1 Interventional

Carmustine in Treating Patients With Recurrent Malignant Glioma

NCT00004028
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, conventional surgery
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2009 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

NCT00591630
View directory record Official record
Conditions
Diffuse Large Cell Lymphoma, Lymphoma
Interventions
Zevalin, Carmustine, Etoposide, Cytarabine, Melphalan, Rituximab, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

NCT00003399
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, in vitro-treated peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma

NCT01130194
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Combination of treatment modalities
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

NCT00233987
View directory record Official record
Conditions
Lymphoma
Interventions
carmustine, cyclophosphamide, etoposide, melphalan, autologous-autologous tandem hematopoietic stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
53
States / cities
Sacramento, California • Boise, Idaho • Maywood, Illinois + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 22, 2026, 5:49 AM EDT
Terminated Phase 3 Interventional Results available

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

NCT02366663
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
90-Yttrium Ibritumomab tiuxetan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous Hematopoietic Stem Cell Transplant, Rituximab
Radiation · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 22, 2026, 5:49 AM EDT
Withdrawn Phase 1 Interventional

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

NCT02343666
View directory record Official record
Conditions
Human Immunodeficiency Virus 1 Positive, Stage I Adult Hodgkin Lymphoma, Stage I Adult Non-Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult Non-Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Non-Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Non-Hodgkin Lymphoma
Interventions
C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs, Carmustine, Filgrastim, Laboratory Biomarker Analysis, O6-Benzylguanine, Plerixafor
Biological · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 66 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Sep 22, 2026, 5:49 AM EDT
Terminated Not applicable Interventional

Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis

NCT03591861
View directory record Official record
Conditions
Pediatric Brain Tumor
Interventions
Ketogenic diet, BCNU
Procedure · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 22, 2026, 5:49 AM EDT
Terminated Phase 3 Interventional

S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease

NCT00005090
View directory record Official record
Conditions
Lymphoma
Interventions
bleomycin sulfate, carmustine, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, vinblastine, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 22, 2026, 5:49 AM EDT
Not listed Phase 3 Interventional

Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas

NCT00003788
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, lomustine, porfimer sodium, procarbazine hydrochloride, neoadjuvant therapy, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Colorado Health Foundation
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Englewood, Colorado • Buffalo, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

NCT00005613
View directory record Official record
Conditions
Lymphoma
Interventions
cyclophosphamide, etoposide, BCNU
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 55 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2010
U.S. locations
2
States / cities
Fort Myers, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

NCT00005961
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
13
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

NCT00005803
View directory record Official record
Conditions
Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cyclosporine, Cytarabine, Etoposide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Therapeutic Autologous Lymphocytes, Total-Body Irradiation
Procedure · Drug · Other + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2018
U.S. locations
4
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Autologous Transplant in HIV Patients (BMT CTN 0803)

NCT01141712
View directory record Official record
Conditions
Lymphoma, HIV
Interventions
Autologous transplant, BCNU, Etoposide, Cytarabine, Melphalan
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
15 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
16
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 22, 2026, 5:49 AM EDT
Withdrawn Phase 2 Interventional

NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

NCT02348255
View directory record Official record
Conditions
Adult Brain Glioblastoma, Recurrent Adult Brain Neoplasm
Interventions
Electric Field Therapy, Bevacizumab, Carmustine, Quality-of-Life Assessment
Procedure · Biological · Drug + 1 more
Lead sponsor
University of California, Davis
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Sacramento, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 22, 2026, 5:49 AM EDT
Not listed Phase 2 Interventional

Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma

NCT00283543
View directory record Official record
Conditions
Newly Diagnosed Supratentorial Malignant Glioma
Interventions
Gliadel Wafer, Temozolomide, Limited field radiation
Drug · Procedure
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years to 72 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 30, 2007 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional

Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme

NCT00003417
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
218
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

NCT00003413
View directory record Official record
Conditions
Ovarian Cancer
Interventions
filgrastim, carmustine, cisplatin, melphalan, paclitaxel, peripheral blood stem cell transplantation, surgical procedure
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

NCT00477035
View directory record Official record
Conditions
Leukemia, Multiple Myeloma
Interventions
CIK cells, etoposide, bcnu, cyclophosphamide, gemcitabine, vinorelbine, melphalan
Drug
Lead sponsor
Sally Arai
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 22, 2026, 5:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

NCT04421378
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
Drug · Radiation · Device
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 22, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

NCT00632827
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma
Interventions
Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection, Granulocyte-colony stimulating factor (G-CSF), Pegfilgrastim, Cyclophosphamide, Vincristine, Leucovorin, Methotrexate, Doxorubicin Hydrochloride, Cytarabine, Etoposide, Carmustine, Denileukin diftitox
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 22, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

NCT00482053
View directory record Official record
Conditions
Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL), Malignant Lymphoma, Non-Hodgkin
Interventions
Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation (TLI), Rituximab, Carmustine, Etoposide, Filgrastim, Anti-thymocyte globulin (ATG), Cyclosporine, Mycophenolate mofetil (MMF), Cyclophosphamide, Acetaminophen, Diphenhydramine, Hydrocortisone, Methylprednisolone
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT03072771
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Blinatumomab, Autologous stem cell transplant, Carmustine, Etoposide, Cytarabine, Melphalan, Peripheral blood draws
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 22, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma

NCT00569985
View directory record Official record
Conditions
Lymphoma
Interventions
lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells, carmustine, cyclophosphamide, etoposide, autologous hematopoietic stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 22, 2026, 5:49 AM EDT